Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sputnik V Vaccine Team ‘Working With EMA To Start Rolling Review’

Executive Summary

After a few false starts, it seems that the EU regulator has begun preparing the ground for a review of Russia’s adenovirus-based COVID-19 vaccine.

You may also be interested in...



Russia’s Sputnik V COVID-19 Vaccine Starts EU Rolling Review

The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.

Slovakia Becomes Second EU Country To OK Use Of Russian Vaccine

While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.

Coronavirus Notebook: Africa Backs IP Waiver Proposal, CEOs To Face EU Parliamentary Hearing On Vaccine Supply

Sanofi and GSK have restarted their Phase II vaccine study, Australia is allowing public advertising of coronavirus vaccines, and Sputnik V has landed in Mexico.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS143825

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel